ES2104712T3 - Adyuvantes y vacunas mejorados. - Google Patents

Adyuvantes y vacunas mejorados.

Info

Publication number
ES2104712T3
ES2104712T3 ES91913213T ES91913213T ES2104712T3 ES 2104712 T3 ES2104712 T3 ES 2104712T3 ES 91913213 T ES91913213 T ES 91913213T ES 91913213 T ES91913213 T ES 91913213T ES 2104712 T3 ES2104712 T3 ES 2104712T3
Authority
ES
Spain
Prior art keywords
antigen
isotype
present
adjuvants
admixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913213T
Other languages
English (en)
Inventor
Robert L Hunter
Kuni K Takayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2104712T3 publication Critical patent/ES2104712T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COADYUVANTES QUE, CUANDO SE MEZCLAN CON UN ANTIGENO Y SE ADMINISTRAN A UN HUMANO O A UN ANIMAL, INDUCIRAN UNA RESPUESTA INMUNE MAS INTENSA AL ANTIGENO QUE CUANDO EL ANTIGENO SE SUMINISTRA SOLO. EN MUCHOS CASOS, EL COADYUVANTE QUE SE DESCRIBE EN LA INVENCION INCREMENTARA LA ACTIVIDAD TOTAL DE ANTICUERPOS DE UN ISOTIPO ESPECIFICO QUE SON ESPECIFICOS PARA EL ANTIGENO. POR EJEMPLO, EN LOS RATONES, CUANDO EL COADYUVANTE DE LA INVENCION SE MEZCLA CON UN ANTIGENO CONVENCIONAL, EL ISOTIPO QUE SE PRODUCE EN EL RATON CAMBIA DE UN ISOTIPO PREDOMINANTEMENTE IGG1 A UN ISOTIPO MAS PROTECTOR IGG2 Y, EN ALGUNOS CASOS, A UN ISOTIPO IGG3. DE ESTA FORMA, MEDIANTE LA PRACTICA DE LA PRESENTE INVENCION, SE PUEDEN MEJORAR LOS EFECTOS PROTECTORES TOTALES DE VACUNAS CONVENCIONALES.
ES91913213T 1990-06-27 1991-06-27 Adyuvantes y vacunas mejorados. Expired - Lifetime ES2104712T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54483190A 1990-06-27 1990-06-27
US71680791A 1991-06-21 1991-06-21

Publications (1)

Publication Number Publication Date
ES2104712T3 true ES2104712T3 (es) 1997-10-16

Family

ID=27067746

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913213T Expired - Lifetime ES2104712T3 (es) 1990-06-27 1991-06-27 Adyuvantes y vacunas mejorados.

Country Status (17)

Country Link
EP (1) EP0536302B1 (es)
JP (1) JPH0832639B2 (es)
KR (1) KR100218138B1 (es)
CN (1) CN1060027A (es)
AT (1) ATE157259T1 (es)
AU (1) AU655593B2 (es)
BR (1) BR9106601A (es)
CA (1) CA2086097C (es)
DE (1) DE69127445T2 (es)
DK (1) DK0536302T3 (es)
ES (1) ES2104712T3 (es)
GR (1) GR3025341T3 (es)
IE (1) IE912257A1 (es)
IL (1) IL98655A0 (es)
NZ (1) NZ238731A (es)
PT (1) PT98119B (es)
WO (1) WO1992000101A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3723231B2 (ja) * 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5407585A (en) * 1993-08-16 1995-04-18 Exxon Chemical Patents Inc. Method of demulsifying water-in-oil emulsions
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
AU6358898A (en) * 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CN102580081B (zh) * 2012-02-22 2014-07-02 中国医学科学院医学生物学研究所 Nad、氢氧化铝复合佐剂及含该复合佐剂的疫苗
CN113527417B (zh) * 2021-07-05 2022-09-27 中国医学科学院放射医学研究所 一种含氟基团的自组装多肽纳米佐剂及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants

Also Published As

Publication number Publication date
AU655593B2 (en) 1995-01-05
CA2086097C (en) 2001-06-12
PT98119A (pt) 1992-04-30
BR9106601A (pt) 1993-04-20
PT98119B (pt) 1998-12-31
AU8286191A (en) 1992-01-23
DE69127445D1 (de) 1997-10-02
WO1992000101A1 (en) 1992-01-09
CA2086097A1 (en) 1991-12-28
ATE157259T1 (de) 1997-09-15
CN1060027A (zh) 1992-04-08
NZ238731A (en) 1996-02-27
JPH05507498A (ja) 1993-10-28
EP0536302B1 (en) 1997-08-27
JPH0832639B2 (ja) 1996-03-29
KR100218138B1 (en) 1999-09-01
EP0536302A1 (en) 1993-04-14
DK0536302T3 (da) 1997-09-29
EP0536302A4 (en) 1993-08-04
IL98655A0 (en) 1992-07-15
GR3025341T3 (en) 1998-02-27
IE912257A1 (en) 1992-01-01
DE69127445T2 (de) 1998-03-19

Similar Documents

Publication Publication Date Title
ES2104712T3 (es) Adyuvantes y vacunas mejorados.
DE69332518D1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
ATE217196T1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
DK0534618T3 (da) Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus
DE69033728D1 (de) Impfstoffkonjugat
EP1379270A4 (en) METHOD FOR INDUCING IMMUNTOLERANCE
ZA93216B (en) Vaccine containing acemannan as an adjuvant.
Edington et al. The protection of rabbits against the herpesvirus of malignant catarrhal fever by inactivated vaccines
ATE128729T1 (de) Impfstoff gegen nematoden.
DE69301733D1 (de) Impfstoffe gegen Metazoen-Parasiten
ATE211923T1 (de) Parenterale immunisierung gegen rotavirus
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
White An evaluation of immunoglobulin isotype expression in immunity to the rodent malarial parasite, Plasmodium Yoelii
DE69322960D1 (de) Empfängnisverhütender impfstoff
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
Kiseleva et al. Comparative study of the concentration of antibodies and protective activity to Pseudomonas aeruginosa in the preparations of gamma globulin and IgM-enriched immunoglobulin.
Watanabe et al. Immunity in cholera
Abdeen Anti-Adult Worm Antibodies From Irradiated Cercariae-Immunized Rabbits Passively Transfer Immunity To Schistosoma haematobium-Infected Mice.
ELISA-IgG Rajesh K. Gupta, Carole L. Varanelli, Paul Griffin, Donald FH Wallah and George R. Siber.“Adjuvant properties of non-phospholipid liposomes (Novasomes@) in experimental animals for human vaccine antigens”. Vaccine 14 (3): 219-225, 1996.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 536302

Country of ref document: ES